EBS
Price
$6.83
Change
+$0.06 (+0.89%)
Updated
Jun 26 closing price
Capitalization
120.07M
46 days until earnings call
VTRS
Price
$9.12
Change
+$0.23 (+2.59%)
Updated
Jun 26 closing price
Capitalization
14.18B
41 days until earnings call
Interact to see
Advertisement

EBS vs VTRS

Header iconEBS vs VTRS Comparison
Open Charts EBS vs VTRSBanner chart's image
Emergent Biosolutions
Price$6.83
Change+$0.06 (+0.89%)
Volume$851.57K
Capitalization120.07M
Viatris
Price$9.12
Change+$0.23 (+2.59%)
Volume$11.39M
Capitalization14.18B
EBS vs VTRS Comparison Chart in %
Loading...
EBS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VTRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EBS vs. VTRS commentary
Jun 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EBS is a Hold and VTRS is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 27, 2025
Stock price -- (EBS: $6.83 vs. VTRS: $9.12)
Brand notoriety: EBS and VTRS are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: EBS: 72% vs. VTRS: 78%
Market capitalization -- EBS: $120.07M vs. VTRS: $14.18B
EBS [@Pharmaceuticals: Other] is valued at $120.07M. VTRS’s [@Pharmaceuticals: Other] market capitalization is $14.18B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.8B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EBS’s FA Score shows that 1 FA rating(s) are green whileVTRS’s FA Score has 2 green FA rating(s).

  • EBS’s FA Score: 1 green, 4 red.
  • VTRS’s FA Score: 2 green, 3 red.
According to our system of comparison, both EBS and VTRS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EBS’s TA Score shows that 4 TA indicator(s) are bullish while VTRS’s TA Score has 5 bullish TA indicator(s).

  • EBS’s TA Score: 4 bullish, 4 bearish.
  • VTRS’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, VTRS is a better buy in the short-term than EBS.

Price Growth

EBS (@Pharmaceuticals: Other) experienced а +8.24% price change this week, while VTRS (@Pharmaceuticals: Other) price change was +3.99% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +114.19%. For the same industry, the average monthly price growth was +75.16%, and the average quarterly price growth was +85.33%.

Reported Earning Dates

EBS is expected to report earnings on Aug 12, 2025.

VTRS is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (+114.19% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VTRS($14.2B) has a higher market cap than EBS($120M). VTRS has higher P/E ratio than EBS: VTRS (238.80) vs EBS (17.73). VTRS YTD gains are higher at: -24.762 vs. EBS (-28.556). VTRS has higher annual earnings (EBITDA): 3.52B vs. EBS (-518.2M). VTRS has more cash in the bank: 1.18B vs. EBS (112M). EBS has less debt than VTRS: EBS (860M) vs VTRS (18.4B). VTRS has higher revenues than EBS: VTRS (15.4B) vs EBS (1.02B).
EBSVTRSEBS / VTRS
Capitalization120M14.2B1%
EBITDA-518.2M3.52B-15%
Gain YTD-28.556-24.762115%
P/E Ratio17.73238.807%
Revenue1.02B15.4B7%
Total Cash112M1.18B9%
Total Debt860M18.4B5%
FUNDAMENTALS RATINGS
EBS vs VTRS: Fundamental Ratings
EBS
VTRS
OUTLOOK RATING
1..100
535
VALUATION
overvalued / fair valued / undervalued
1..100
57
Fair valued
12
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9494
PRICE GROWTH RATING
1..100
4758
P/E GROWTH RATING
1..100
111
SEASONALITY SCORE
1..100
85n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VTRS's Valuation (12) in the null industry is somewhat better than the same rating for EBS (57) in the Biotechnology industry. This means that VTRS’s stock grew somewhat faster than EBS’s over the last 12 months.

VTRS's Profit vs Risk Rating (100) in the null industry is in the same range as EBS (100) in the Biotechnology industry. This means that VTRS’s stock grew similarly to EBS’s over the last 12 months.

VTRS's SMR Rating (94) in the null industry is in the same range as EBS (94) in the Biotechnology industry. This means that VTRS’s stock grew similarly to EBS’s over the last 12 months.

EBS's Price Growth Rating (47) in the Biotechnology industry is in the same range as VTRS (58) in the null industry. This means that EBS’s stock grew similarly to VTRS’s over the last 12 months.

VTRS's P/E Growth Rating (1) in the null industry is in the same range as EBS (11) in the Biotechnology industry. This means that VTRS’s stock grew similarly to EBS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EBSVTRS
RSI
ODDS (%)
Bearish Trend 5 days ago
83%
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
67%
Momentum
ODDS (%)
Bullish Trend 1 day ago
73%
Bullish Trend 1 day ago
63%
MACD
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
63%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
64%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
75%
Bullish Trend 1 day ago
61%
Advances
ODDS (%)
Bullish Trend 5 days ago
77%
Bullish Trend 8 days ago
67%
Declines
ODDS (%)
Bearish Trend 11 days ago
89%
Bearish Trend 23 days ago
67%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
67%
Aroon
ODDS (%)
Bullish Trend 1 day ago
73%
Bullish Trend 1 day ago
65%
View a ticker or compare two or three
Interact to see
Advertisement
EBS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VTRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AZTR0.260.01
+2.71%
Azitra
EBC15.230.34
+2.28%
Eastern Bankshares
KNSL476.4010.57
+2.27%
Kinsale Capital Group
FTK14.660.32
+2.23%
Flotek Industries
SAGE9.280.03
+0.32%
Sage Therapeutics